In the VCD-treated murine model of menopause, we have previously shown that circulating FSH levels increase before ovarian failure after the onset of dosing in mice.(14,15) In this study, SpBMD loss was not detected until 2.9 mo after ovarian failure, which corresponds to day 154 after the onset of dosing. This evidence concerns the gene BRD2 and ovarian dysfunction.